Conceptio › Archive › HAL (France)
HAL (France)open access

Acceptability and tolerability of risankizumab maintenance therapy administered via on-body injector in patients with Crohn’s disease: Results of the ACCEPT-OBI study

Anthony Buisson et al.
HAL (France) · Papers · License: Open Access
Open Source ↗
acceptability
On-body injector, 0, 1, Acceptability, Advanced therapy, 2, Risankizumab, Crohn disease
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗
Record · ID 796319
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.